{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:33:33Z","timestamp":1775583213538,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NERD) might benefit from aspirin desensitization (AD) as an alternative treatment to standard care. However, there is conflicting evidence regarding its role in bronchial symptoms and asthma exacerbations.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To analyze the clinical effects of AD in terms of lung function, systemic and inhaled steroid use, the frequency of acute asthma exacerbations, and adverse effects in patients with NERD and asthma.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methodology<\/jats:title>\n<jats:p>We identified randomized clinical trials (RCTs) from PubMed, EMBASE, SCOPUS, and EBSCO. We also searched the RCT references for additional studies. Studies comparing AD to placebo in patients with a previous history of pulmonary symptoms triggered by ASA or other NSAIDs or with a positive provocation test to ASA were included.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Primary results<\/jats:title>\n<jats:p>Five studies with 210 participants with NERD were included in this review. The study duration ranged from 3 to 6 months. Overall, the risk of bias across the included RCTs was low. We identified 3 studies evaluating lung function, 2 of which reported a significant improvement in FEV1 in the AD group after 6 months, while the other reported no difference among the treatments. Due to high heterogeneity, we did not pool the results. The remaining primary outcomes were reported only in a single study each, hindering their interpretation. Secondary outcomes revealed reduced symptom and medication scores in patients with AD.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Due to the small number of studies included in this systematic review, conclusions should be made with caution. AD shows a trend towards improving lung function (FEV1) following 6 months of treatment, although no conclusions can be made regarding the use of corticosteroids or the frequency of acute exacerbations. AD appears to reduce both symptom and medication scores. Additional RCTs are needed to fully assess the efficacy of AD in reducing bronchial symptoms in patients with NERD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0247871","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T17:39:59Z","timestamp":1616780399000},"page":"e0247871","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Aspirin desensitization in NSAID-exacerbated respiratory disease and its outcomes in the clinical course of asthma: A systematic review of the literature and meta-analysis"],"prefix":"10.1371","volume":"16","author":[{"given":"Isabel","family":"Eraso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saveria","family":"Sangiovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana I.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-9154","authenticated-orcid":true,"given":"Liliana","family":"Fern\u00e1ndez-Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"issue":"1","key":"pone.0247871.ref001","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)\u2014a EAACI position paper","volume":"74","author":"ML Kowalski","year":"2019","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"11","key":"pone.0247871.ref002","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/all.12269","article-title":"Aspirin 300 mg\/day is effective for treating aspirin-exacerbated respiratory disease","volume":"68","author":"S Comert","year":"2013","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"pone.0247871.ref003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin\u2010exacerbated respiratory disease among asthmatic patients: a meta\u2010analysis of the literature","volume":"135","author":"JP Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0247871.ref004","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/all.12941","article-title":"Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GALEN).","volume":"71","author":"Makowska","year":"2016","journal-title":"Allergy"},{"key":"pone.0247871.ref005","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jaci.2013.10.006","article-title":"Phenotypes determined by cluster analysis in severe or difficult\u2010to\u2010treat asthma","volume":"133","author":"M Schatz","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0247871.ref006","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/all.12941","article-title":"Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GALEN)","volume":"71","year":"2016","journal-title":"Allergy"},{"key":"pone.0247871.ref007","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/all.12629","article-title":"NSAID\u2010exacerbated respiratory disease: a meta\u2010analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity","volume":"70","author":"DR Morales","year":"2015","journal-title":"Allergy"},{"issue":"2","key":"pone.0247871.ref008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1385\/CRIAI:24:2:113","article-title":"Natural history and clinical features of aspirin-exacerbated respiratory disease","volume":"24","author":"JM Fahrenholz","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"pone.0247871.ref009","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"AA White","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0247871.ref010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.iac.2012.10.003","article-title":"Genetics of hypersensitivity to aspirin and nonsteroidal anti\u2010inflammatory drugs","volume":"33","author":"SH Kim","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"key":"pone.0247871.ref011","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1034\/j.1399-3003.2000.016003432.x","article-title":"Natural history of aspirin induced asthma. AIANE Investigators. European Network on Aspirin Induced Asthma","volume":"16","author":"A Szczeklik","year":"2000","journal-title":"Eur Respir J"},{"key":"pone.0247871.ref012","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2008.09.048","article-title":"Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin\u2010exacerbated respiratory disease","volume":"123","author":"AP Hope","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"pone.0247871.ref013","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.iac.2016.06.006","article-title":"Performing Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease.","volume":"36","author":"JD Waldram","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"pone.0247871.ref014","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1440-1843.2005.00740.x","article-title":"Contribution of aspirinin tolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan","volume":"10","author":"F Yoshimine","year":"2005","journal-title":"Respirology"},{"key":"pone.0247871.ref015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-1-4614-8603-9_6","article-title":"Management of asthma: the current US and European guidelines","volume":"795","author":"AP Reddy","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"pone.0247871.ref016","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1046\/j.1365-2745.2002.01501.x","article-title":"The effect of leukotriene\u2010modifier drugs on aspirin\u2010induced asthma and rhinitis reactions","volume":"32","author":"MP Berges-Gimeno","year":"2002","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"pone.0247871.ref017","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.iac.2016.06.011","article-title":"Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.","volume":"36","author":"J Hill","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"pone.0247871.ref018","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-6749(99)70324-6","article-title":"Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses","volume":"104","author":"PJ Daffern","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"pone.0247871.ref019","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1067\/mai.2003.1487","article-title":"Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management","volume":"111","author":"SD Szczeklik A","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"pone.0247871.ref020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.iac.2012.11.003","article-title":"Mechanisms of aspirin desensitization","volume":"33","author":"T Burnett","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"key":"pone.0247871.ref021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mai.2003.7","article-title":"Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"111","author":"M Berges-Gimeno","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"pone.0247871.ref022","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/alr.22520","article-title":"Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review","volume":"10","author":"N Lariv\u00e9e","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"issue":"12","key":"pone.0247871.ref023","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/alr.22428","article-title":"Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis","volume":"9","author":"DK Chu","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"pone.0247871.ref024","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin\u2010exacerbated respiratory disease","volume":"5","author":"WW Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pr"},{"key":"pone.0247871.ref025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1027\/0838-1925.15.6.246","article-title":"Nasal polyposis in aspirin\u2010hypersensitive patients with asthma (aspirin triad) and aspirin\u2010tolerant patients.","volume":"6","author":"ML Kowalski","year":"2003","journal-title":"Allergy Clin Immunol Int \u2010 J World Allergy Org"},{"key":"pone.0247871.ref026","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.iac.2012.11.002","article-title":"Rhinosinusitis and nasal polyps in aspirin\u2010exacerbated respiratory disease","volume":"33","author":"J PC Mullol","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"pone.0247871.ref027","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clim.2015.05.012","article-title":"Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial","volume":"160","author":"H Esmaeilzadeh","year":"2015","journal-title":"Clin Immunol"},{"issue":"5","key":"pone.0247871.ref028","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/all.12131","article-title":"Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease","volume":"68","author":"K Fruth","year":"2013","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"4","key":"pone.0247871.ref029","first-page":"1639","article-title":"Clinical and immunological efficacy of aspirin desensitization in nasal polyp patients with aspirin-exacerbated respiratory disease","volume":"16","author":"N Mortazavi","year":"2017","journal-title":"Iran J Pharm Res"},{"issue":"4","key":"pone.0247871.ref030","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0091-6749(84)90361-0","article-title":"Aspirin-sensitive rhinosinusitis asthma: A double-blind crossover study of treatment with aspirin","volume":"73","author":"DD Stevenson","year":"1984","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"pone.0247871.ref031","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: A double-blind study","volume":"134","author":"M Swierczy\u0144ska-Kr\u0119pa","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"pone.0247871.ref032","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.","volume":"32","author":"KM Walters","year":"2018","journal-title":"Am J Rhinol Allergy"},{"issue":"9","key":"pone.0247871.ref033","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1398-9995.2008.01658.x","article-title":"Long-term treatment with aspirin desensitization: A prospective clinical trial comparing 100 and 300 mg aspirin daily","volume":"63","author":"A Rozsasi","year":"2008","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"1","key":"pone.0247871.ref034","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaci.2006.09.011","article-title":"Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease","volume":"119","author":"JY Lee","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0247871.ref035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials","volume":"392","author":"PM Rothwell","year":"2018","journal-title":"Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T17:40:42Z","timestamp":1616780442000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247871"}},"subtitle":[],"editor":[{"given":"Christophe","family":"Leroyer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247871","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]}}}